---
title: "Moderna surges 8% on cancer vaccine trial success, analyst upgrades"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297688197.md"
description: "Moderna rose 8% as its melanoma vaccine Phase III trial hit key endpoints and five firms upgraded the stock."
datetime: "2026-09-01T19:01:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297688197.md)
  - [en](https://longbridge.com/en/news/297688197.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297688197.md)
generator: "portal-rs"
---

# Moderna surges 8% on cancer vaccine trial success, analyst upgrades

Moderna(MRNA.US) 盘中涨超**8%**，现报**151.655 美元**。

此次异动主要受公司癌症疫苗管线进展及资本市场动作推动。Moderna 与 Merck 联合开发的 mRNA 个性化癌症疫苗 mRNA-4157（Intismeran）在针对完全切除的 IIB 至 IV 期黑色素瘤患者的 III 期临床试验 INTerpath-001 中，成功达成无复发生存期（RFS）和无远处转移生存期（DMFS）两项核心终点。该突破性数据已推动公司股价在 8 月累计上涨**152%**，成为当月标普 500 指数表现最佳个股。

公司近期完成**26 亿美元**可转换优先票据发行，较原计划的 20 亿美元规模上调，资金将用于肿瘤管线投资及债务管理。受积极临床数据推动，Argus Research 等五家机构近期连续上调 Moderna 评级，Argus 将评级从「持有」上调至「买入」，目标价**180 美元**。公司将于 9 月 14 日出席摩根士丹利全球医疗保健会议，并于 9 月 23 日参加 Bernstein Insights Healthcare Forum。

### Related Stocks

- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)

## Related News & Research

- [Moderna (NASDAQ:MRNA) Insider Sells $485,766.45 in Stock](https://longbridge.com/en/news/297959605.md)
- [Moderna Chief Legal Officer Shannon Thyme Klinger disposes of USD 485,271.45 in common shares](https://longbridge.com/en/news/297958452.md)
- [Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It](https://longbridge.com/en/news/298134130.md)
- [Moderna Raises $3.0 Billion via 2032 Zero-Coupon Converts; Adds Capped Calls to Limit Dilution](https://longbridge.com/en/news/297697426.md)
- [15 Stocks to Watch With Short Squeeze Potential](https://longbridge.com/en/news/297819476.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**